Safety and tolerability of metoprolol OROS in hypertension treatment

N. Feliciano, P. H. Kasarjian, J. I. McMillen, K. E. Grau, C. Kessler, H. B. Stevelman, L. B. Hogan, W. J. Mroczek, R. J. Goldstein, R. Montoro

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

One hundred twenty-six patients with mild to moderate hypertension responsive to β-adrenergic blocking agents-alone or in combination with other antihypertensive drugs-entered this open-label, multicenter study designed to evaluate the safety and tolerability of metoprolol OROS (metoprolol fumarate). Metoprolol OROS was given once daily for 14 weeks in doses ranging from 100 to 600 mg. Satisfactory blood pressure control was achieved by 85% of the patients at doses between 100 and 400 mg. Mean diastolic blood pressure was maintained at or below 90 mm Hg. Adverse reactions were experienced by 29% of the patients; most of these reactions were mild or moderate, and none was unexpected for treatment with a β-blocker. Only three patients withdrew because of adverse reactions. The results of this study indicate that metoprolol OROS given once daily is safe and well tolerated.

Original languageEnglish (US)
Pages (from-to)490-494
Number of pages5
JournalAmerican Heart Journal
Volume120
Issue number2
DOIs
StatePublished - Aug 1990

Bibliographical note

Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.

Fingerprint Dive into the research topics of 'Safety and tolerability of metoprolol OROS in hypertension treatment'. Together they form a unique fingerprint.

Cite this